- Home
- ATNI vs VNDA Comparison
ATNI vs VNDA Comparison
Compare ATNI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- VNDA
- Stock Information
- Founded
- ATNI 1987
- VNDA 2002
- Country
- ATNI United States
- VNDA United States
- Employees
- ATNI N/A
- VNDA N/A
- Industry
- ATNI Telecommunications Equipment
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- VNDA Health Care
- Exchange
- ATNI Nasdaq
- VNDA Nasdaq
- Market Cap
- ATNI 226.4M
- VNDA 260.0M
- IPO Year
- ATNI 1991
- VNDA 2006
- Fundamental
- Price
- ATNI $19.84
- VNDA $4.43
- Analyst Decision
- ATNI
- VNDA Strong Buy
- Analyst Count
- ATNI 0
- VNDA 3
- Target Price
- ATNI N/A
- VNDA $14.00
- AVG Volume (30 Days)
- ATNI 44.1K
- VNDA 677.7K
- Earning Date
- ATNI 11-05-2025
- VNDA 10-29-2025
- Dividend Yield
- ATNI 5.59%
- VNDA N/A
- EPS Growth
- ATNI N/A
- VNDA N/A
- EPS
- ATNI N/A
- VNDA N/A
- Revenue
- ATNI $724,308,000.00
- VNDA $212,074,000.00
- Revenue This Year
- ATNI $1.57
- VNDA $14.32
- Revenue Next Year
- ATNI $2.09
- VNDA $37.05
- P/E Ratio
- ATNI N/A
- VNDA N/A
- Revenue Growth
- ATNI N/A
- VNDA 11.12
- 52 Week Low
- ATNI $13.76
- VNDA $3.81
- 52 Week High
- ATNI $23.60
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- ATNI 80.69
- VNDA 34.70
- Support Level
- ATNI $14.16
- VNDA $4.27
- Resistance Level
- ATNI $19.37
- VNDA $4.49
- Average True Range (ATR)
- ATNI 1.04
- VNDA 0.22
- MACD
- ATNI 0.63
- VNDA -0.09
- Stochastic Oscillator
- ATNI 100.00
- VNDA 7.69
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.